Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-04-08 00:00:00 ET · period of report 2024-04-04 · accession 0001415889-24-010520 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-08 | 2024-04-04 | ELVN | Ballal Rahul D. | Dir | S - Sale+OE | $19.15 | -3,485 | 22.3K | -13% | -$66.7K |
| D | 2024-04-08 | 2024-04-04 | ELVN | Ballal Rahul D. | Dir | M - OptEx | $12.60 | +3,485 | 25.8K | +16% | +$43.9K |
| D | 2024-04-08 | 2024-04-04 | ELVN | Ballal Rahul D. | Dir | M - OptEx | $0.00 | -3,485 | 62.4K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-04 | S | D | 3,485 | $19.15 | 22,341 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $19.05 to $19.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2024-04-04 | M | A | 3,485 | $12.60 | 25,826 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-04-04 | M | D | 3,485 | $0.00 | 62,420 | D | $12.60 · — to 2028-10-19 | 3,485 Common Stock | (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |